Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02534467




Registration number
NCT02534467
Ethics application status
Date submitted
13/08/2015
Date registered
27/08/2015
Date last updated
22/08/2019

Titles & IDs
Public title
Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?
Scientific title
Montelukast as Adjunct Treatment in Children With Atopic Dermatitis
Secondary ID [1] 0 0
35095A
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dermatitis, Atopic 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Montelukast

Experimental: Montelukast-Standard - 8 weeks of montelukast and standard therapy crossing over to 8 weeks of only standard therapy

Active comparator: Standard-Montelukast - 8 weeks of standard therapy only crossing over to 8 weeks of montelukast and standard therapy


Treatment: Drugs: Montelukast
daily dose according to age for 8 weeks out of 16 weeks of assessment
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in SCORAD Scoring Atopic Dermatitis index (Units on a scale)
Timepoint [1] 0 0
at 8 weeks
Secondary outcome [1] 0 0
Change in SCORAD Scoring Atopic Dermatitis index (Units on a scale)
Timepoint [1] 0 0
at 4 weeks
Secondary outcome [2] 0 0
Change in children's Dermatology Life Quality Index cDLQI (Units on a scale)
Timepoint [2] 0 0
at 8 weeks
Secondary outcome [3] 0 0
Change in children's Dermatology Life Quality Index cDLQI (Units on a scale)
Timepoint [3] 0 0
at 4 weeks

Eligibility
Key inclusion criteria
- Patients aged 6-16 years old with moderate to severe atopic dermatitis (SCORAD >25) despite topical therapy (corticosteroids and emollients) for at least 2 months Patients aged 6-16 years old with moderate to severe atopic dermatitis (SCORAD >25) despite immunosuppressive therapy (azathioprine, cyclosporine, methotrexate) for at least 2 months
Minimum age
6 Years
Maximum age
16 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients with mild atopic dermatitis (SCORAD <25) Patients who have received phototherapy in the past 8 weeks Patients with history of sensitivity to leukotriene receptor antagonists

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Crossover
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
9/07/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
4/12/2018
Sample size
Target
Accrual to date
Final
60
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
The Royal Children's Hospital - Parkville
Recruitment postcode(s) [1] 0 0
3052 - Parkville

Funding & Sponsors
Primary sponsor type
Other
Name
Murdoch Childrens Research Institute
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Monash University
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
An open-label (outcome assessor blinded) prospective crossover cohort study of children 6-16 years assessing effects of Montelukast on moderate to severe atopic dermatitis.
Trial website
https://clinicaltrials.gov/study/NCT02534467
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
John C Su, FRACP, FACD
Address 0 0
Murdoch Children's Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02534467